VEGFA and retinopathy of prematurity: The RAINBOW trial of 2019, which evaluated the efficacy and safety of the anti-VEGF intravitreal antibody Ranibizumab [11], with a shorter half-life and potentially lower systemic toxicity than bevacizumab, [12] (7.19 and 9.82 [13] subsequent days) was groundbreaking for the treatment of ROP.